Completion of Moderna’s Vaccine Production Line at Novocol Pharma Enhances Ontario’s Biomanufacturing Strength

• Vaccines manufactured at Moderna’s state-of-the-art Canadian mRNA facility will be filled and packaged
  at Ontario-based Novocol, supporting domestic end-to-end production.

CAMBRIDGE, ON – Moderna and Novocol Pharma are proud to announce the
inauguration of a new mRNA vaccine fill-finish production line at Novocol’s facility in Cambridge,
Ontario. Originally announced in May 2023, this partnership, supported by the Ontario Together Fund,
represents a significant step forward in both Ontario’s and Canada’s biomanufacturing capabilities. It
also helps ensure a rapid response capacity for future health emergencies and a secure domestic
respiratory vaccine supply.

Together with Moderna’s new facility in Quebec and ongoing partnership with the federal government,
the new production line positions Canada as a leader in vaccine supply and highlights the power of
public-private partnerships in safeguarding public health. Locally produced COVID-19 vaccines are
anticipated to be ready by the 2025 fall vaccination campaign. This initiative is generating and
supporting high-skilled employment opportunities.

Quotes:

“This new fill-finish line is a testament to Ontario’s leadership and Moderna’s commitment to fortify
Canada’s healthcare infrastructure and pandemic preparedness. By collaborating with Novocol Pharma,
we are building a resilient, end-to-end mRNA production process that will make vaccines accessible to
Canadians when they need them most.” Stefan Raos, General Manager of Moderna Canada

“The expansion of Novocol Pharma’s fill-finish capacity and partnership with Moderna represents a
major milestone in the growth of biomanufacturing in Canada. Together, we will serve our country’s
needs for domestic vaccine supply and drive economic growth through advanced manufacturing right
here in Ontario.” Atif Zia, COO of Septodont and President of Novocol Pharma

“I’m thrilled to help Moderna celebrate the launch of the new production line at Novocol in Cambridge.
This new line, which our government was pleased to support with a $4 million investment, will
strengthen the province’s growing life sciences sector, create good-paying jobs throughout the region
and provide people in Ontario with faster, more reliable access to life-saving vaccines when we need
them.” Premier Doug Ford.

“Ontario has become a hub of healthcare innovation and technology that is connecting more people to
the care they need, attracting global biomanufacturing partners like Moderna. The new state-of-the-art
fill and finish production line at Novocol in Cambridge is championing made-in-Ontario solutions that
will build healthier communities in our province, and across the country, for years to come.” Sylvia
Jones, Deputy Premier and Minister of Health.

“Having attracted over $5 billion in investments from leading biomanufacturers over the last six years,
Ontario’s life sciences ecosystem continues to lead the development of life-changing medicines and
technologies. As we look to build upon this successful partnership with Moderna, the new vaccine fillfinish
line at Novocol Pharma will play an important role in strengthening our province’s domestic
medical supply chains to ensure we remain resilient in the face of future challenges, while at the
forefront of opportunity.” Vic Fedeli, Ontario Minister of Economic Development, Job Creation and
Trade.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA
technology, Moderna is reimagining how medicines are made and transforming how we treat and
prevent disease for everyone. By working at the intersection of science, technology and health for more
than a decade, the company has developed medicines at unprecedented speed and efficiency, including
one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious
diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global
team driven by Moderna values and mindsets to responsibly change the future of human health,
Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more
information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter),
Facebook, Instagram, YouTube and LinkedIn.

About Novocol Pharma, a Septodont Company

Novocol Pharma is a sterile injectable fill-finish organization based in Cambridge, Ontario. The company
provides contract clinical and commercial-scale manufacturing services for global customers. For more
information, please visit www.novocolpharma.com.

Moderna Contacts:

Canada Media:
Sacha Kennedy
Director, Communications & Media Relations, Canada
sacha.kennedy@modernatx.com

International Media:
Luke Mircea Willats
Senior Director, Corporate Communications
Luke.Mirceawillats@modernatx.com

Novocol Pharma Contacts:
Dan Newman
Communications Manager
dnewman@septodont.com

Original source here.